Russia said Tuesday that its Sputnik V coronavirus vaccine is more than 91% effective, according to the latest data from its ongoing Phase 3 trials.
Data obtained 28 days after the first dose and seven days after the second dose showed the vaccine was 91.4% effective, according to a press release published on the Sputnik-V Twitter account.
Preliminary data obtained 42 days after the first dose -- 21 days after the second dose -- indicates the vaccine’s efficacy could be higher than 95%.
The Gamaleya National Research Centre for Epidemiology and Microbiology hopes to publish the data from the Phase 3 trials in an international medical journal following a peer review, the statement continued.
Some experts have accused Russia of cutting corners with its vaccine development -- a claim Moscow has denied.
The calculations were based on the analysis of data of 18,794 volunteers who received both the first and second doses of the Sputnik V vaccine or placebo.
The latest interim analysis came after 39 confirmed Covid-19 cases among Phase 3 trial participants who received the vaccine or a placebo, according to the press release from the Russian Direct Investment Fund and Gamaleya Institute.
The statement added there were no unexpected adverse events during the trials and monitoring of participants is ongoing.
Around 40,000 volunteers are taking part in the Phase 3 trials in Russia, of which more than 22,000 volunteers were vaccinated with the first dose and more than 19,000 with the first and second doses, according to the statement.